BRISBANE, June 19, 2026, 08:06 (AEST)
- ALS shares finished Thursday at A$23.36, slipping 0.26%. The stock bounced back after touching A$22.825 during the session.
- The company is set to join the S&P/ASX 50 before the open on June 22, taking the spot from Pro Medicus.
- Macquarie Securities will manage on-market buying for the dividend reinvestment plan. The final dividend of A$0.231 is set for July 3.
ALS Ltd closed at A$23.36 on Thursday, down 6 cents. Shares bounced off a session low of A$22.83 to end at the day’s high. The testing firm is set to join the S&P/ASX 50 before Monday, taking the spot of Pro Medicus, the medical-imaging software group.
That shift is key for index-trackers, since these funds mimic the benchmark and usually swap holdings when the index lineup changes. ALS also has its on-market share purchase for the dividend reinvestment plan, or DRP, open now, so trading in the short term could show fund activity more than any new take on earnings.
ALS traded 2.51 million shares, above the average 1.72 million. ALS slipped 0.26%. The S&P/ASX 200 dropped 0.62% to 8,911.10. That move snapped four straight gains for the index.
ALS didn’t release an operating update Thursday. Its most recent filing, from Tuesday, said Macquarie Securities (Australia) Ltd is running the DRP buyback. ALS said it would only issue new shares if it couldn’t finish the on-market purchases.
ALS Global set its final dividend at 23.1 Australian cents per share, 30% franked, to be paid July 3. The DRP will use the five-day volume-weighted average price from June 17 to June 23, with no discount applied.
May posted its full-year numbers with revenue up 10.7% to A$3.32 billion. Underlying net profit after tax, adjusted for one-offs, jumped 25.8% to A$381.2 million. The underlying operating margin hit 18.0%.
ALS chairman Nigel Garrard said the company “demonstrated the diversification benefits of its operating model.” CEO Malcolm Deane said he saw “robust financial performance in FY26.” Commodities revenue jumped 18.8%, and underlying operating profit was up 25.9%. ALS lists Bureau Veritas, Intertek and SGS as its formal comparator group.
Thursday’s trading action looks more technical than driven by earnings. Shares closed at the session high even as the market dropped, pointing to solid demand. But index adds and DRP buying don’t affect the company’s revenue or cash flow. After those flows end, mineral sample volumes and pricing likely take the lead again.
ALS warned the mineral exploration run could slow, and Life Sciences could need more time to recover its weaker segments. The company said its Environmental unit is dealing with soft trading in the Americas, some internal quality and cost issues still being fixed, and some project delays after the U.S. government shutdown. Margins might fall from FY26 levels if the volume mix worsens.
S&P/ASX 200 futures slipped 0.5% before Friday’s session, putting broad-market pressure in focus. With the index shift set on Monday, investors now look at the DRP pricing close on June 23, the dividend payment on July 3, and the annual meeting on July 28.
